Tag: MONOGRAPH

  • Elinzanetant

    Dual neurokinin-1 (NK1) and neurokinin-3 (NK3) receptor antagonist for non-hormonal treatment of menopausal vasomotor symptoms

    A non-hormonal, orally bioavailable dual NK1/NK3 receptor antagonist developed through GlaxoSmithKline, NeRRe Therapeutics, KaNDy Therapeutics, and Bayer for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, distinguished from selective NK3 antagonists by concurrent blockade of substance P signaling and consequent additive benefits on sleep, mood, and thermoregulatory dysregulation.

    Abstract

    Elinzanetant (Lynkuet; BAY3427080; formerly NT-814 and GSK1144814) is a potent and selective dual antagonist of the neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors, developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause and with endocrine therapy for hormone receptor-positive breast cancer. The compound received its first regulatory approval in the United Kingdom in July 2025, followed by approvals in Australia, Canada, Switzerland, and the United States, where it was approved by the Food and Drug Administration on October 24, 2025, under the trade name Lynkuet at a recommended dose of 120 mg orally once daily at bedtime. Elinzanetant is the first and only approved dual NK1/NK3 receptor antagonist, mechanistically distinct from fezolinetant (Veozah), which acts solely on the NK3 receptor. The dual mechanism targets kisspeptin/neurokinin B/dynorphin (KNDy) neurons in the hypothalamic arcuate nucleus, where neurokinin B (NKB) acting through NK3 receptors initiates thermoregulatory dysregulation responsible for hot flashes, and substance P (SP) acting through NK1 receptors amplifies KNDy neuronal activity and contributes to sleep disruption, mood disturbance, and peripheral vasodilation. By antagonizing both receptor subtypes, elinzanetant addresses the composite symptom burden of menopause rather than isolated hot flash frequency alone. The compound exhibits high affinity for human NK1 receptors (pKi 8.7 to 10.2) and NK3 receptors (pKi 8.0 to 8.8), with greater than 300-fold selectivity for NK1 and greater than 100-fold selectivity for NK3 over off-target receptors. Pharmacokinetics are characterized by rapid oral absorption (median Tmax approximately 1 hour), absolute oral bioavailability of 52 percent, extensive plasma protein binding (99.7 percent), a large volume of distribution (137 L), and a long elimination half-life of approximately 45 hours that supports once-daily dosing. Metabolism is predominantly CYP3A4-mediated, producing three active metabolites with comparable NK1/NK3 potency at approximately 39 percent of parent plasma exposure. Excretion is predominantly fecal (90 percent as metabolites). The clinical evidence base comprises the OASIS Phase 3 program: OASIS 1 and OASIS 2 (12-week placebo-controlled studies in approximately 400 postmenopausal women each), OASIS 3 (52-week long-term study in 628 women), and OASIS 4 (12-week study in women receiving breast cancer endocrine therapy). All trials met primary endpoints, demonstrating statistically significant and clinically meaningful reductions in VMS frequency and severity at weeks 4 and 12, with onset of effect as early as week 1. Secondary endpoints showed significant improvements in sleep disturbances, menopause-related quality of life, and mood. Long-term efficacy was maintained through 52 weeks in OASIS 3 with no signal of hepatotoxicity, endometrial hyperplasia, or endometrial malignancy. The most common adverse events are headache (7.8 percent) and fatigue (5 percent). Elinzanetant is contraindicated in pregnancy, in severe hepatic impairment, and with concomitant strong CYP3A4 inhibitors. This monograph reviews the chemistry, synthesis, and stereochemistry of elinzanetant; the dual-receptor pharmacology in molecular and neurophysiological detail; the comprehensive human pharmacokinetic record; the clinical evidence base across the OASIS program and the dose-finding SWITCH-1 study; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations for research applications; the adverse-event and safety signal profile; and a comparative assessment of five alternative compounds for vasomotor symptom management against elinzanetant on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1627Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • LDN-193189

    Selective bone morphogenetic protein (BMP) type I receptor kinase inhibitor targeting ALK2 and ALK3

    A pyrazolopyrimidine-scaffold small molecule derived from dorsomorphin structure-activity optimization, selectively inhibiting BMP type I receptor kinases ALK2 and ALK3 at low-nanomolar potency with 200-fold selectivity over TGF-beta signaling, and widely adopted as a research tool for BMP pathway dissection, directed stem cell differentiation, and preclinical modeling of fibrodysplasia ossificans progressiva and diffuse intrinsic pontine glioma.

    Abstract

    LDN-193189 (DM-3189; CAS 1062368-24-4) is a cell-permeable, small-molecule inhibitor of bone morphogenetic protein (BMP) type I receptor serine/threonine kinases, developed through structure-activity relationship optimization of dorsomorphin at the Brigham and Women’s Hospital and Harvard Medical School laboratories of Paul B. Yu. The compound inhibits activin receptor-like kinase 2 (ALK2, also designated ACVR1) with an IC50 of approximately 5 nM and activin receptor-like kinase 3 (ALK3, also designated BMPR1A) with an IC50 of approximately 30 nM, while exhibiting approximately 200-fold selectivity for BMP receptors over the transforming growth factor-beta (TGF-beta) type I receptor ALK5 and negligible activity against ALK4 and ALK7 at concentrations below 500 nM. The mechanism of action involves competitive binding at the ATP-binding pocket of BMP type I receptor kinases, preventing receptor autophosphorylation and blocking downstream phosphorylation of the canonical signaling effectors Smad1, Smad5, and Smad8. In addition to canonical Smad pathway inhibition, LDN-193189 suppresses BMP-induced non-canonical signaling through the p38 mitogen-activated protein kinase (MAPK) and Akt (protein kinase B) pathways, providing broader coverage of BMP-dependent intracellular signaling than Smad-selective interventions alone.

    The compound originated from the 2008 Cuny, Yu, and colleagues structure-activity relationship study that optimized the pyrazolo[1,5-a]pyrimidine scaffold of dorsomorphin, a compound itself discovered in 2008 by Yu et al. through a phenotypic zebrafish embryo screen of approximately 7,500 bioactive compounds for agents that could dorsalize the developing embryo and thereby phenocopy loss-of-function mutations in the BMP signaling pathway. Dorsomorphin, while the first small-molecule BMP pathway inhibitor identified, exhibited substantial off-target activity against AMP-activated protein kinase (AMPK), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor (PDGFR), limiting its utility as a selective BMP pathway probe. LDN-193189 retained the central pyrazolopyrimidine core but incorporated a quinoline moiety and a piperazinylphenyl substituent that conferred markedly improved potency and selectivity for BMP type I receptors over the off-target kinases that compromised dorsomorphin’s pharmacological profile.

    LDN-193189 has become one of the most widely used pharmacological tools for interrogating BMP signaling in developmental biology, stem cell biology, and disease modeling. In stem cell biology, the compound is a core component of the dual SMAD inhibition protocol (in combination with the TGF-beta/Activin/Nodal inhibitor SB431542) developed by Chambers et al. (2009) for the efficient directed differentiation of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) toward neuroectodermal and neural progenitor fates, a protocol that has become the standard method for generating central nervous system neurons from human pluripotent stem cells. In disease modeling, the compound has been extensively characterized in preclinical models of fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder caused by gain-of-function mutations in the ACVR1/ALK2 gene that produce constitutive BMP pathway activation and progressive heterotopic ossification of soft tissues. Treatment of mice expressing constitutively active ALK2 with LDN-193189 reduced heterotopic bone formation in the landmark Yu et al. (2008) Nature Medicine study. The compound has also demonstrated preclinical efficacy in orthotopic xenograft models of diffuse intrinsic pontine glioma (DIPG) harboring ACVR1 mutations, extending survival in treated animals. Additional research applications span iron metabolism and hepcidin regulation (through BMP6-dependent Smad signaling in hepatocytes), pulmonary arterial hypertension modeling, chondrogenesis and osteogenesis research, and cancer biology.

    LDN-193189 has not entered human clinical trials and is not a registered medicine in any jurisdiction. The compound is classified as a research tool and is supplied by multiple commercial vendors (Selleck Chemicals, MedChemExpress, Cayman Chemical, Tocris, Sigma-Aldrich, Stemgent/REPROCELL, and others) as the free base or hydrochloride salt at greater than 98 percent purity. In vivo pharmacokinetic characterization in mice has demonstrated oral bioavailability and brain penetration sufficient for central nervous system target engagement, though metabolic liabilities including aldehyde oxidase-dependent metabolism and generation of reactive piperazinyl iminium intermediates have been identified as concerns for clinical translation and have motivated the development of next-generation analogs (LDN-212854, LDN-214117, ML347, DMH1, K02288) with improved selectivity or metabolic profiles. This monograph reviews the chemistry, synthesis, and structural pharmacology of LDN-193189; the molecular mechanism of BMP type I receptor kinase inhibition; the preclinical pharmacology across FOP, DIPG, stem cell, iron metabolism, and cancer applications; the pharmacokinetic and metabolic characterization; sourcing, reconstitution, and handling; stack interactions with other signaling pathway modulators; the adverse-event and safety signal from preclinical studies; and a comparative assessment of five alternative BMP pathway inhibitors against LDN-193189 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1638Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Levosimendan

    Calcium sensitizer with phosphodiesterase III inhibition and ATP-sensitive potassium channel activation

    A pyridazinone-dinitrile inodilator developed at Orion Corporation as a calcium-sensitizing positive inotrope for acutely decompensated heart failure, distinguished from conventional inotropes by its ability to enhance myocardial contractility without increasing intracellular calcium concentration or myocardial oxygen consumption, and by its long-lived active metabolite OR-1896 that sustains hemodynamic effects for days beyond infusion cessation.

    Abstract

    Levosimendan, the (R)-enantiomer of simendan, is a pyridazinone-derivative calcium sensitizer and positive inotropic agent developed by Orion Corporation (Finland) and approved in approximately 60 countries for the short-term treatment of acutely decompensated severe chronic heart failure in situations where conventional therapy is not considered adequate. The compound exerts its principal pharmacological effects through three complementary mechanisms: calcium-dependent binding to the N-terminal domain of cardiac troponin C, which stabilizes the calcium-troponin C interaction and enhances myofilament sensitivity to calcium without increasing intracellular calcium concentration; selective inhibition of phosphodiesterase III (PDE3) in cardiac and vascular smooth muscle, which elevates cyclic adenosine monophosphate and contributes to positive inotropy and vasodilation; and opening of ATP-sensitive potassium channels (both sarcolemmal and mitochondrial) in vascular smooth muscle and cardiomyocytes, producing peripheral and coronary vasodilation and conferring cardioprotective effects against ischemia-reperfusion injury. The composite pharmacology produces the characteristic inodilator profile: simultaneous enhancement of cardiac contractility, reduction of cardiac preload and afterload, and improvement in coronary perfusion, all achieved without a proportional increase in myocardial oxygen demand.

    The pharmacokinetic profile of levosimendan is distinguished by the formation of an active metabolite, OR-1896, through intestinal reduction of the parent compound to the amino-derivative OR-1855 followed by hepatic N-acetylation. OR-1896 exhibits calcium-sensitizing and PDE3-inhibitory activity comparable to the parent compound and possesses an elimination half-life of approximately 75 to 80 hours in heart failure patients, compared to approximately 1 hour for the parent. This metabolite formation pathway introduces N-acetyltransferase 2 (NAT2) acetylator phenotype as a determinant of OR-1896 exposure, with slow acetylators demonstrating lower OR-1896 concentrations and potentially diminished sustained hemodynamic effects. The prolonged activity of OR-1896 sustains hemodynamic improvement for 7 to 9 days following cessation of a standard 24-hour intravenous infusion, a property unique among clinically available inotropic agents.

    The clinical evidence base comprises six principal Phase II and Phase III randomized controlled trials (LIDO, RUSSLAN, CASINO, REVIVE-I, REVIVE-II, SURVIVE) enrolling more than 3,000 patients with acute decompensated heart failure, supplemented by extensive registry data, meta-analyses, and ongoing investigation in cardiac surgery, cardiogenic shock, septic cardiomyopathy, pulmonary hypertension, right ventricular failure, and advanced heart failure with intermittent ambulatory infusion protocols. The LIDO trial demonstrated hemodynamic superiority and a 31-day survival advantage over dobutamine. The SURVIVE trial, the largest randomized comparison (1,327 patients), demonstrated superior reduction in B-type natriuretic peptide but did not achieve the primary endpoint of reduced 180-day all-cause mortality compared to dobutamine, though subgroup analyses favored levosimendan in patients on chronic beta-blocker therapy and those with prior heart failure history. Levosimendan is marketed as Simdax (Orion Corporation) and is not approved by the United States Food and Drug Administration; the original new drug application was withdrawn in 1999 following a request for additional trials. This monograph reviews the chemistry and stereochemistry, the triple-mechanism molecular pharmacology, the unique metabolite-driven pharmacokinetic profile, the comprehensive clinical evidence base, sourcing considerations, reconstitution and handling, drug interactions, adverse events, and a comparative assessment against five alternative inotropic agents on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1623Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pegozafermin

    GlycoPEGylated fibroblast growth factor 21 (FGF21) analog with extended half-life for metabolic and hepatic disease

    A long-acting glycoPEGylated analog of fibroblast growth factor 21 engineered to recapitulate the endocrine metabolic activity of native FGF21, developed by 89bio for the treatment of metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.

    Abstract

    Pegozafermin (BIO89-100) is a glycoPEGylated recombinant analog of human fibroblast growth factor 21 (FGF21), a hepatokine central to the regulation of lipid metabolism, glucose homeostasis, and energy expenditure. The compound was engineered using site-specific glycosylation and PEGylation to extend the circulating half-life from approximately 0.5 to 2 hours (native FGF21) to 55 to 100 hours, enabling once-weekly or once-every-two-week subcutaneous administration while preserving the receptor binding profile of the native hormone. Pegozafermin signals through the FGF receptor 1c (FGFR1c) and FGF receptor 3c in complex with the obligate coreceptor beta-klotho (KLB), activating the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade and downstream transcription factors that govern hepatic de novo lipogenesis, adipose tissue adiponectin secretion, fatty acid oxidation, and insulin sensitivity. The compound was originally developed by Teva Pharmaceutical Industries and subsequently licensed to 89bio, Inc. in 2019 for global development (excluding Israel).

    In the Phase 2b ENLIVEN trial (Loomba et al., 2023, New England Journal of Medicine), 222 patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and stage F2 or F3 fibrosis were randomized to pegozafermin 15 mg weekly, 30 mg weekly, 44 mg every two weeks, or placebo for 24 weeks. The co-primary histological endpoints were met at both the 30 mg weekly and 44 mg every-two-week doses: fibrosis improvement of at least one stage without worsening of steatohepatitis was achieved in 26 percent and 27 percent of treated patients, respectively, compared with 7 percent on placebo. NASH resolution without fibrosis worsening was achieved in 23 percent and 26 percent, respectively, compared with 2 percent on placebo. Hepatic fat fraction measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) decreased by 48.2 percent (30 mg weekly) and 41.9 percent (44 mg every two weeks) versus 5.0 percent on placebo. Alanine aminotransferase levels normalized in 59 to 65 percent of treated patients versus 24 percent on placebo, and the fibrosis biomarker PRO-C3 decreased by 17 to 18 percent versus a 6.4 percent increase on placebo.

    In the Phase 2 ENTRIGUE trial in severe hypertriglyceridemia (Bhatt et al., 2023, Nature Medicine), pegozafermin at doses of 9 to 27 mg weekly or 36 mg every two weeks produced a pooled median triglyceride reduction of 57.3 percent versus 11.9 percent on placebo, with 79.7 percent of treated patients achieving triglycerides below 500 mg/dL compared with 29.4 percent on placebo. Secondary lipid endpoints included reductions in non-HDL cholesterol (18.3 percent), apolipoprotein B (10.5 percent), apolipoprotein C3 (41.9 percent), and increases in HDL cholesterol of up to 44.5 percent at the 27 mg weekly dose.

    Safety across both trials was characterized by mild-to-moderate gastrointestinal adverse events (nausea, diarrhea) and injection site reactions. No hepatotoxicity, drug-induced liver injury, or clinically significant bone density changes were observed. One treatment-related serious adverse event (acute pancreatitis in a patient with gallbladder sludge) was reported in the ENLIVEN trial.

    Pegozafermin received Breakthrough Therapy designation from the United States Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency for the treatment of MASH with fibrosis in September 2023. The compound is currently in Phase 3 development in the ENLIGHTEN program (MASH with fibrosis and compensated cirrhosis) and the ENTRUST program (severe hypertriglyceridemia). This monograph reviews the compound identification, discovery and development history, molecular pharmacology of the FGF21 signaling axis, pharmacokinetics, preclinical pharmacology, clinical evidence base, sourcing and quality verification, reconstitution and handling, stack interactions and combinations, adverse events and safety signal, and a comparative assessment of five alternative metabolic liver disease candidates against pegozafermin on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1630Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Aficamten

    Selective small-molecule allosteric inhibitor of cardiac beta-myosin heavy chain (MYH7) ATPase activity

    A next-generation cardiac myosin inhibitor developed by Cytokinetics as CK-3773274, engineered for optimized pharmacokinetic properties relative to mavacamten, approved by the United States Food and Drug Administration in December 2025 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy under the trade name MYQORZO.

    Abstract

    Aficamten (CK-3773274, trade name MYQORZO) is a selective, allosteric, reversible small-molecule inhibitor of cardiac myosin motor activity developed by Cytokinetics, Inc. for the treatment of hypertrophic cardiomyopathy (HCM). The compound reduces myocardial contractility by stabilizing a weak actin-binding, pre-power-stroke state of the beta-cardiac myosin head, thereby decreasing the number of functional myosin cross-bridges available during each cardiac cycle and attenuating the left ventricular outflow tract (LVOT) obstruction that drives symptoms in obstructive HCM. Aficamten binds to an allosteric site between the upper 50 kDa and lower 50 kDa subdomains of the myosin catalytic domain, overlapping with the blebbistatin binding pocket but distinct from the mavacamten binding site, and dramatically slows phosphate release from the myosin ATPase cycle to a rate slower than the conventional super-relaxed state.

    The compound was engineered to address pharmacokinetic limitations of mavacamten, the first-in-class cardiac myosin inhibitor. Aficamten achieves a plasma elimination half-life of approximately 75 to 100 hours (compared to 7 to 9 days for mavacamten), reaches steady-state plasma concentrations within approximately 2 weeks of daily dosing (compared to approximately 6 weeks for mavacamten), demonstrates reversibility of pharmacodynamic effects within 24 to 48 hours, exhibits a shallow exposure-response relationship that widens the therapeutic window, and is metabolized by multiple cytochrome P450 enzymes (CYP2C9, CYP3A4, CYP2D6, CYP2C19) rather than predominantly by the polymorphic CYP2C19, thereby reducing the drug-drug interaction burden and eliminating the requirement for CYP metabolizer genotyping.

    Clinical development of aficamten has proceeded through a comprehensive program. The Phase 1 dose-escalation study in 102 healthy participants demonstrated dose-proportional pharmacokinetics, dose-dependent reductions in left ventricular ejection fraction (LVEF), and favorable tolerability with no serious adverse events. The Phase 2 REDWOOD-HCM trial in patients with symptomatic obstructive HCM demonstrated statistically significant reductions in resting and post-Valsalva LVOT gradients, with 78.6 to 92.9 percent of patients achieving target gradient reduction at 10 weeks. The pivotal Phase 3 SEQUOIA-HCM trial randomized 282 patients with symptomatic obstructive HCM to aficamten or placebo for 24 weeks and met its primary endpoint of improved peak oxygen uptake (pVO2), with a least-squares mean difference of 1.74 mL/kg/min (p = 0.000002), along with statistically significant improvements in all 10 prespecified secondary endpoints including NYHA functional class, Kansas City Cardiomyopathy Questionnaire scores, and LVOT gradient reduction. The Phase 3 MAPLE-HCM trial demonstrated superiority of aficamten monotherapy over metoprolol monotherapy, with a pVO2 least-squares mean difference of 2.3 mL/kg/min (p < 0.0001). The Phase 3 ACACIA-HCM trial in 516 patients with non-obstructive HCM met both dual primary endpoints for symptom burden and exercise capacity improvement.

    The United States Food and Drug Administration approved aficamten on December 19, 2025, for the treatment of adults with symptomatic obstructive HCM to improve functional capacity and symptoms, marketed as MYQORZO. The approval includes a boxed warning regarding the risk of heart failure due to systolic dysfunction and a Risk Evaluation and Mitigation Strategy (REMS) requiring echocardiographic monitoring. The principal adverse reaction observed at greater than 5 percent incidence above placebo was hypertension (8 percent versus 2 percent). LVEF reduction below 50 percent occurred in 3.5 percent of aficamten-treated patients in SEQUOIA-HCM compared to 0.7 percent on placebo; all instances were mild, reversible, and not associated with clinical heart failure events. This monograph reviews the chemistry, mechanism, pharmacokinetics, preclinical and clinical evidence, safety profile, handling considerations, and comparative assessment of aficamten against five alternative agents for the management of hypertrophic cardiomyopathy.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1622Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pelacarsen

    GalNAc3-conjugated 2′-MOE antisense oligonucleotide targeting apolipoprotein(a) mRNA for lipoprotein(a) reduction

    A hepatocyte-directed, triantennary N-acetylgalactosamine-conjugated antisense oligonucleotide developed by Ionis Pharmaceuticals and licensed to Novartis, designed to selectively reduce circulating lipoprotein(a) concentrations by RNase H1-mediated degradation of apolipoprotein(a) mRNA in hepatocytes, currently under evaluation in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial.

    Abstract

    Pelacarsen (ISIS 681257; also designated IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx, and TQJ230) is a second-generation, hepatocyte-directed antisense oligonucleotide (ASO) conjugated to a triantennary N-acetylgalactosamine (GalNAc3) ligand, designed to reduce circulating lipoprotein(a) [Lp(a)] concentrations by selective inhibition of apolipoprotein(a) [apo(a)] synthesis in the liver. The compound targets the messenger RNA transcribed from the LPA gene, binding with high specificity and triggering RNase H1-mediated cleavage and subsequent degradation of the transcript, thereby preventing translation of the apo(a) protein that is the defining structural component of the Lp(a) particle. The GalNAc3 conjugation exploits the high-density expression of the asialoglycoprotein receptor (ASGPR) on hepatocyte surfaces to achieve rapid, selective uptake into the liver, the exclusive site of apo(a) biosynthesis, conferring a 20- to 30-fold improvement in potency relative to the unconjugated parent compound IONIS-APO(a)Rx and enabling clinically effective Lp(a) lowering at substantially reduced doses and extended dosing intervals.

    Lipoprotein(a) is a genetically determined, independent, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve stenosis (CAVS), and thrombotic events. Plasma Lp(a) concentrations are primarily determined by LPA gene variation and are minimally responsive to lifestyle modification or conventional lipid-lowering pharmacotherapy including statins, ezetimibe, and PCSK9 inhibitors. Approximately 20 to 25 percent of the global population carries Lp(a) concentrations above 50 mg/dL, the threshold at which epidemiological and Mendelian randomization data consistently demonstrate elevated cardiovascular risk. Prior to the development of targeted Lp(a)-lowering agents, no pharmacotherapy had demonstrated selective, potent, and sustained reduction of Lp(a) in a manner suitable for chronic cardiovascular risk management.

    In the pivotal Phase 2b dose-ranging trial (Tsimikas et al., 2020, New England Journal of Medicine), pelacarsen administered subcutaneously to 286 patients with established ASCVD and Lp(a) concentrations of 60 mg/dL or greater produced dose-dependent Lp(a) reductions of 35 to 80 percent across five dosing regimens (20 mg every 4 weeks, 40 mg every 4 weeks, 60 mg every 4 weeks, 20 mg every 2 weeks, and 20 mg every week) over 6 to 12 months, with the 20 mg weekly regimen achieving approximately 80 percent mean reduction. The compound was well tolerated; the principal adverse events were mild injection site reactions. On the basis of these results, the 80 mg monthly subcutaneous dose was selected for the Phase 3 cardiovascular outcomes program.

    The Lp(a)HORIZON trial (NCT04023552) is a randomized, double-blind, placebo-controlled Phase 3 study enrolling 8,323 patients with established cardiovascular disease and Lp(a) concentrations of 70 mg/dL or greater, designed to evaluate whether pelacarsen 80 mg administered subcutaneously once monthly reduces the incidence of major adverse cardiovascular events (MACE; composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization) relative to placebo on a background of optimized standard-of-care therapy. Enrollment was completed in 2022; topline results are anticipated in 2026. A companion Phase 3 trial (Lp(a)FRONTIERS CAVS) evaluates pelacarsen in calcific aortic valve stenosis progression. This monograph reviews the chemistry, conjugation technology, and molecular pharmacology of pelacarsen; the comprehensive pharmacokinetic record including hepatic impairment and ethnic pharmacokinetic data; the preclinical and clinical evidence base; sourcing and handling considerations; stack interactions; adverse events and safety signal; and a comparative assessment of five Lp(a)-lowering agents against pelacarsen on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1625Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Resmetirom

    Liver-directed, beta-selective thyroid hormone receptor agonist (thyromimetic)

    A first-in-class, orally administered, hepatocyte-targeted partial agonist of thyroid hormone receptor beta developed by Madrigal Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis, and the first pharmacotherapy approved by the United States Food and Drug Administration for this indication.

    Abstract

    Resmetirom (MGL-3196, VIA-3196; marketed as Rezdiffra) is a first-in-class, orally administered, small-molecule, liver-directed partial agonist of the thyroid hormone receptor beta (THR-beta) that received accelerated approval from the United States Food and Drug Administration on March 14, 2024, for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH) with moderate to advanced liver fibrosis (stages F2 to F3), in conjunction with diet and exercise. Resmetirom is distinguished from earlier thyromimetic compounds by approximately 28-fold functional selectivity for THR-beta over THR-alpha, hepatocyte-directed uptake mediated by organic anion transporting polypeptide 1B1 (OATP1B1), and a liver-to-plasma concentration ratio of approximately 8:1, properties that collectively minimize the extrahepatic thyrotoxic effects (tachycardia, bone loss, skeletal muscle wasting) that terminated development of prior thyroid hormone receptor agonists including eprotirome and sobetirome. The molecular mechanism involves activation of THR-beta in hepatocytes, promoting fatty acid beta-oxidation, mitochondrial biogenesis, mitophagy, and autophagy while inhibiting de novo lipogenesis; these effects reduce intrahepatic triglyceride accumulation and attenuate the inflammatory and fibrotic cascades characteristic of progressive steatohepatitis. In the pivotal Phase 3 MAESTRO-NASH trial (n = 888, biopsy-confirmed noncirrhotic MASH with F2 to F3 fibrosis), resmetirom at 100 mg daily achieved MASH resolution without fibrosis worsening in 36 percent of patients versus 13 percent on placebo at 52 weeks, and fibrosis improvement by at least one stage without worsening of MASH activity in 28 percent versus 15 percent on placebo, both co-primary endpoints reaching statistical significance. Secondary endpoints demonstrated reductions in low-density lipoprotein cholesterol (16.3 percent), apolipoprotein B (16.5 percent), and triglycerides (23.4 percent), consistent with the hepatic metabolic mechanism. Pharmacokinetics are characterized by oral absorption with a median time to peak concentration of approximately 4 hours, greater than 99 percent plasma protein binding, a median terminal half-life of 4.5 hours, metabolism predominantly through cytochrome P450 2C8 (CYP2C8), and elimination principally via feces (67 percent) with a minor renal component (24 percent). The principal adverse events are diarrhea and nausea, which are generally mild to moderate and self-limiting. Clinically significant drug interactions include inhibition of organic anion transporting polypeptide transporters (elevating statin exposures) and CYP2C8-mediated metabolic interactions. This monograph reviews the chemistry, synthesis, and structural pharmacology of resmetirom; the thyroid hormone receptor biology and mechanism of action in detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology; the clinical evidence base across the MAESTRO trial program; sourcing and quality verification for research-grade material; reconstitution and handling; stack-interaction considerations; adverse-event signal and safety profile; and a comparative assessment of five alternative MASH pharmacotherapy candidates against resmetirom on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1633Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Stemoxydine

    Prolyl-4-hydroxylase competitive inhibitor and hypoxia-inducible factor 1-alpha stabilizer (2-oxoglutarate analog)

    A synthetic pyridinedicarboxylate ester developed by L’Oreal Research and Innovation as a topical hypoxia-mimetic agent that stabilizes HIF-1 alpha in perifollicular tissue, shortens the kenogen latency phase of the hair cycle, and increases visible scalp hair density through reactivation of dormant follicles.

    Abstract

    Stemoxydine (diethyl pyridine-2,4-dicarboxylate; CAS 41438-38-4) is a cell-permeable, competitive inhibitor of the 2-oxoglutarate- and iron(II)-dependent enzyme prolyl-4-hydroxylase (P4H, also designated HIF-PHD or EGLN), developed by L’Oreal Research and Innovation as a topical cosmetic active for the promotion of visible scalp hair density. The compound belongs to the pyridinedicarboxylate structural class, a group of 2-oxoglutarate analogs that occupy the cosubstrate-binding pocket of P4H isoforms and chelate the catalytic iron center, thereby preventing the oxygen-dependent hydroxylation of proline residues 402 and 564 on the alpha subunit of hypoxia-inducible factor 1 (HIF-1 alpha). Pharmacological inactivation of P4H results in constitutive stabilization of HIF-1 alpha under normoxic conditions, mimicking the transcriptional program of cellular hypoxia without actual oxygen deprivation. In the hair follicle, this hypoxia-mimetic signaling activates a downstream cascade that includes upregulation of vascular endothelial growth factor (VEGF), BNIP3, EGLN3, and carbonic anhydrase IX (CA9), genes whose expression profiles in stemoxydine-treated follicles cultured under normoxia closely mirror those of follicles cultured under true hypoxic conditions.

    The principal biological effect of topical stemoxydine at the 5% concentration used in vehicle-controlled clinical studies is the shortening of the kenogen phase, the interval between telogen hair shedding and subsequent anagen reinitiation during which the follicle remains visibly empty. By reducing this latency period, stemoxydine increases the proportion of follicles bearing a visible hair shaft at any given time, producing a measurable increase in scalp hair density without altering the intrinsic rate of hair shaft elongation or the duration of anagen itself. Three vehicle-controlled studies conducted by L’Oreal in male volunteers demonstrated statistically significant increases in hair density: a pilot study of 16 men showed a 4.5% density increase versus a 0.3% decrease with vehicle (p = 0.04); a second study of 23 men showed an 11% increase versus 7% with vehicle (p = 0.029); and a pivotal study of 100 men showed an 8% increase versus 4% with vehicle (p = 0.036), corresponding to an estimated 1,700 additional visible hairs over 90 days of once-daily application. A subsequent randomized study in 79 female volunteers (Juchaux et al. 2020) demonstrated that a formulation combining 5% stemoxydine with 0.25% resveratrol significantly increased hair density from 1.5 months of use, with the combination producing synergistic stabilization of HIF-1 alpha protein and enhanced expression of downstream target genes compared to either component alone.

    Stemoxydine is not classified as a pharmaceutical agent in any jurisdiction and has not received regulatory approval from the United States Food and Drug Administration or any equivalent authority for the treatment of androgenetic alopecia or any other medical condition. It is marketed exclusively as a cosmetic ingredient under L’Oreal brand names (Neogenic, Serioxyl, Serioxyl Advanced Denser Hair) and is available in research-grade form as diethyl pyridine-2,4-dicarboxylate from multiple chemical suppliers. The compound is generally well tolerated in topical application at the 5% concentration, with no skin intolerance recorded in vehicle-controlled trials. The safety profile beyond short-term topical use has not been characterized in peer-reviewed literature, and independent clinical validation outside of manufacturer-sponsored studies remains limited. This monograph reviews the chemistry, molecular pharmacology, pharmacokinetics, preclinical biology, clinical evidence, sourcing, handling, stack-interaction considerations, adverse-event profile, and a comparative assessment of five topical hair density agents against stemoxydine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1621Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Trimetazidine

    Piperazine-derived partial fatty acid oxidation inhibitor (p-FOX) and metabolic modulator of myocardial energy substrate utilization

    A cytoprotective anti-ischemic piperazine developed by Laboratoires Servier as the first metabolic modulator of cardiac energy substrate preference, distinguished from hemodynamic antianginal agents by its oxygen-sparing shift from long-chain fatty acid beta-oxidation to glucose oxidation through selective inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

    Abstract

    Trimetazidine (1-(2,3,4-trimethoxybenzyl)piperazine) is a metabolic anti-ischemic agent developed by Laboratoires Servier in the late 1960s and first marketed in France in 1978 under the trade name Vastarel. It is registered in approximately 100 countries for the treatment of stable angina pectoris as add-on therapy to hemodynamic antianginal agents and, in certain jurisdictions, for symptomatic management of vertigo, tinnitus, and visual disturbance of vascular origin, although the European Medicines Agency restricted the latter indications following a 2012 Article 31 referral. The compound is not approved by the United States Food and Drug Administration and is not available in the United States, Canada, or the United Kingdom.

    The molecular mechanism of trimetazidine is metabolic rather than hemodynamic. The compound selectively inhibits the mitochondrial long-chain 3-ketoacyl coenzyme A thiolase (3-KAT, also designated mitochondrial trifunctional protein thiolase), the terminal enzyme in the beta-oxidation spiral of long-chain fatty acids, with an IC50 of approximately 75 nanomolar as originally reported by Kantor et al. (2000) in isolated working rat hearts, although subsequent work by MacInnes et al. (2003) using purified enzyme preparations challenged the direct enzymatic inhibition and proposed alternative upstream targets. The functional consequence of 3-KAT inhibition is a shift in myocardial energy substrate preference from fatty acid oxidation (which consumes more oxygen per mole of ATP generated) to glucose oxidation (which is approximately 12 percent more oxygen-efficient per unit of ATP), thereby preserving myocardial high-energy phosphate pools under ischemic conditions without altering heart rate, blood pressure, coronary blood flow, or rate-pressure product. The compound additionally increases pyruvate dehydrogenase activity, reduces intracellular calcium overload, attenuates reactive oxygen species generation, decreases neutrophil infiltration in ischemic myocardium, and preserves intracellular pH homeostasis during ischemia and reperfusion.

    The clinical evidence base for trimetazidine in stable angina pectoris is extensive. Multiple randomized controlled trials, including the TRIMPOL-I, TRIMPOL-II, and VASCO-angina studies, have demonstrated that trimetazidine as add-on therapy to beta-blockers, calcium channel blockers, or long-acting nitrates produces statistically significant improvements in total exercise duration, time to 1 mm ST-segment depression, and weekly angina attack frequency compared to placebo. The 2024 European Society of Cardiology guidelines for chronic coronary syndromes assign trimetazidine a Class IIb, Level of Evidence B recommendation as add-on antianginal therapy in patients with inadequate symptom control, a downgrade from the prior Class IIa designation that has been criticized by some experts as inconsistent with the available trial evidence. A separate and growing literature supports benefit in heart failure with reduced ejection fraction (HFrEF): multiple meta-analyses (Gao et al. 2011, Zhang et al. 2012, Weng et al. 2024) pooling data from over 1,500 patients have reported mean improvements in left ventricular ejection fraction of 6 to 7.5 percentage points, reductions in cardiac hospitalization (relative risk 0.43), and reductions in all-cause mortality (relative risk 0.47), leading to inclusion of trimetazidine in the 2021 ESC heart failure guidelines at a Class IIb level for relief of persistent angina in heart failure patients.

    Pharmacokinetics are characterized by rapid and near-complete gastrointestinal absorption, approximately 90 percent oral bioavailability, a plasma elimination half-life of approximately 6 hours for the immediate-release formulation (approximately 12 hours for the modified-release 35 mg formulation), renal elimination of approximately 60 percent of the administered dose as unchanged drug, and minimal hepatic cytochrome P450-mediated metabolism with low drug-drug interaction potential. The compound is generally well tolerated; the principal adverse events are gastrointestinal disturbance (nausea, epigastric discomfort), asthenia, headache, and dizziness. The most clinically significant safety signal is the induction of reversible parkinsonian symptoms (rest tremor, bradykinesia, gait disturbance, rigidity) in a small fraction of patients, predominantly elderly, on prolonged therapy. This signal prompted the 2012 EMA Article 31 referral that resulted in new contraindications (Parkinson disease, parkinsonian symptoms, tremor, restless leg syndrome, severe renal impairment) and restriction of indications. Symptoms resolve in most patients within weeks to months of drug discontinuation. This monograph reviews the chemistry, synthesis, and structural pharmacology of trimetazidine; the metabolic mechanism of action in molecular detail; the comprehensive pharmacokinetic profile; the clinical evidence base across angina, heart failure, and investigational indications; sourcing and quality considerations; reconstitution and handling; stack-interaction implications; the adverse-event and safety signal record; and a structured comparative assessment of five alternative metabolic and antianginal agents against trimetazidine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1624Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Esmethadone

    Uncompetitive N-methyl-D-aspartate receptor antagonist with residual low-affinity opioid receptor activity

    The (S)-enantiomer of racemic methadone, developed by Relmada Therapeutics as REL-1017 for major depressive disorder on the basis of low-potency, voltage-dependent uncompetitive NMDA receptor channel blockade with preferential tonic inhibition of GluN2D-containing receptors, negligible clinically relevant opioid agonist activity, and rapid mTORC1- and BDNF-dependent antidepressant-like effects in preclinical models.

    Abstract

    Esmethadone (REL-1017, d-methadone, dextromethadone) is the (S)-enantiomer of the synthetic opioid methadone and a low-potency, voltage-dependent, uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor that was advanced through Phase 3 clinical development by Relmada Therapeutics for the adjunctive and monotherapy treatment of major depressive disorder (MDD). Unlike the (R)-enantiomer levomethadone, which carries the analgesic opioid activity of the racemate, esmethadone exhibits approximately 10-fold lower affinity at mu-opioid receptors and lacks clinically meaningful opioid agonist effects, respiratory depression, reinforcing properties, or physical dependence liability at the doses studied for antidepressant activity. The compound blocks NMDA receptor ion channels with IC50 values in the low micromolar range (approximately 13 to 68 micromolar across GluN2A through GluN2D subunit combinations), with functional selectivity for tonically active GluN2D-containing receptors under physiological magnesium concentrations. This tonic blockade is proposed to disinhibit downstream alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated glutamatergic transmission, activate mammalian target of rapamycin complex 1 (mTORC1) signaling, and increase brain-derived neurotrophic factor (BDNF) expression, producing rapid-onset antidepressant effects comparable in mechanism (though not in potency or dissociative liability) to ketamine and esketamine. Preclinical studies in rodent models of depressive-like behavior (forced swimming test, novelty-suppressed feeding test, female urine sniffing test, chronic unpredictable stress) demonstrated that oral esmethadone produced antidepressant effects comparable to injectable ketamine in magnitude and duration, mediated by mTORC1 signaling in the medial prefrontal cortex and blocked by the selective mTORC1 inhibitor rapamycin. A Phase 1 study in healthy volunteers demonstrated that esmethadone increased circulating BDNF levels, providing translational biomarker support for the preclinical mechanism. Pharmacokinetics are characterized by approximately 70 to 80 percent oral bioavailability, a long elimination half-life exceeding 30 hours that supports once-daily dosing, and hepatic metabolism principally through CYP3A4/5 and CYP2B6 to the inactive metabolite EDDP, with approximately half the dose recovered in urine and 40 percent in feces. The compound is a CYP2D6 inhibitor in vitro, producing clinically relevant increases in exposure of CYP2D6 substrates such as dextromethorphan. The Phase 2a randomized, double-blind, placebo-controlled adjunctive trial in MDD patients with inadequate response to standard antidepressants (Fava et al., American Journal of Psychiatry, 2022) demonstrated rapid and sustained improvement on the Montgomery-Asberg Depression Rating Scale (MADRS) at 25 mg and 50 mg daily doses, with effect sizes of 0.7 to 1.0 and day-14 remission rates of 31 percent and 39 percent versus 5 percent on placebo. No dissociative or psychotomimetic effects were observed. The Phase 3 Reliance I trial (published 2024) did not meet its primary efficacy endpoint, attributed in part to an elevated placebo response during the COVID-19 pandemic enrollment period. A second Phase 3 trial (Reliance II) was initiated, but interim analysis in late 2024 indicated that the study was unlikely to meet its primary efficacy endpoint, and Relmada Therapeutics paused further development of REL-1017. A 12-month open-label extension study in 624 MDD patients confirmed long-term safety and tolerability, with the most common treatment-related adverse events being headache (4.6 percent), nausea (4.2 percent), and dizziness (2.6 percent), no signal for cardiovascular, metabolic, neurological, or sexual adverse events, no suicides or suicide attempts, and no withdrawal syndrome on discontinuation. A dedicated abuse-potential study in recreational drug users demonstrated no meaningful abuse potential. The compound is not approved by any regulatory authority. This monograph reviews the chemistry, stereochemistry, and synthesis of esmethadone; the NMDA receptor pharmacology including subunit selectivity and downstream signaling; the opioid receptor binding profile; comprehensive pharmacokinetics including drug-drug interactions; the preclinical and clinical evidence base across Phase 1, Phase 2, and Phase 3 programs; sourcing and quality considerations; reconstitution and handling; stack interactions; the adverse-event and safety profile; and a comparative assessment of five alternative NMDA receptor-targeting antidepressant candidates against esmethadone on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1586Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.